Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | EED | O75530 | 2/20 | 0.43 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.43 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248879 | 0.85 | KMO (0.41) | PIK3CAAKT1MTOR | |
| SCHEMBL4764912 | 0.83 | GABRP (0.52) | PDK4CYP11B2GRM1GRM5EED | |
| SCHEMBL15000447 | 0.78 | CYP11B2 (0.49) | PDK4CYP11B2GRM1GRM5PIK3CA | |
| SCHEMBL30439316 | 0.77 | PDK4 (0.51) | BTKPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL1804728 | 0.77 | PDK4 (0.51) | BTKPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL18129633 | 0.76 | MAP4K1 (0.55) | BTKCYP11B2PIK3CAJAK1PIK3CD | |
| SCHEMBL115682 | 0.76 | PDK4 (0.54) | BTKPDK4GRM1GRM5EED | |
| SCHEMBL1497809 | 0.76 | NAMPT (0.43) | PDK4CYP11B2GRM1GRM5PIK3CA | |
| SCHEMBL21245699 | 0.76 | PDK4 (0.50) | BTKPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL30198515 | 0.76 | PDK4 (0.50) | BTKPDK4CYP11B2GRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | BTK 17/4885PDK4 2614/4885CYP11B2 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.